Topics

Aurora Kinase A Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

23:26 EST 1 Feb 2020 | BioPortfolio Reports

Aurora Kinase A Pipeline Review, H2 2019


Summary


According to the recently published report 'Aurora Kinase A Pipeline Review, H2 2019'; Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.


Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 Aurora kinase A also known as serine/threonineprotein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression. It plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. It is required for initial activation of CDK1 at centrosomes and normal axon formation. It phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. It regulates KIF2A tubulin depolymerase activity.


The report 'Aurora Kinase A Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 2 and 2 respectively. Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 4 molecules, respectively. Report covers products from therapy areas Oncology which include indications TripleNegative Breast Cancer TNBC, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Gastric Cancer, Hepatocellular Carcinoma, Neuroblastoma, Ovarian Cancer, Pancreatic Cancer, SmallCell Lung Cancer, Solid Tumor, BCell Chronic Lymphocytic Leukemia, Bile Duct Cancer Cholangiocarcinoma, Bladder Cancer, Breast Cancer, Central Nervous System CNS Tumor, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, HighGrade Glioma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Kidney Cancer Renal Cell Cancer, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Lung Cancer, Neuroendocrine Tumors, Peripheral TCell Lymphomas PTCL, Prostate Cancer and Soft Tissue Sarcoma.


Scope


The report provides a snapshot of the global therapeutic landscape for Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1

The report reviews Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects

The report assesses Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aurora Kinase A Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Aurora Kinase A Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Aurora Kinase A Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975"

Quick Search

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...